Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GLP1R | P43220 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1671889 | 0.87 | HTT (0.42) | KDM4EKMT2AALDH1A1RAB9ANOS3 | |
| SCHEMBL1321965 | 0.86 | KMT2A (0.39) | KDM4EKMT2AALDH1A1RAB9ANOS2 | |
| SCHEMBL9378258 | 0.85 | NOS2 (0.44) | KDM4EKMT2AALDH1A1RAB9ANOS3 | |
| SCHEMBL3806604 | 0.84 | KCNH2 (0.41) | KMT2AL3MBTL1ADORA2AADORA2BADORA1 | |
| SCHEMBL8385253 | 0.82 | KCNH2 (0.44) | KDM4EALDH1A1HPGDPKMHSD17B10 | |
| SCHEMBL9378466 | 0.82 | NOS3 (0.34) | KDM4EKMT2AALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL1319508 | 0.79 | KMT2A (0.38) | KDM4EKMT2ARAB9AHTTNPC1 | |
| SCHEMBL21022475 | 0.79 | MAPT (0.33) | KDM4EKMT2AALDH1A1RAB9AHTT | |
| SCHEMBL5751544 | 0.75 | ALDH1A1 (0.45) | KDM4EKMT2AALDH1A1RAB9AGLP1R | |
| SCHEMBL24738810 | 0.75 | CYP2D6 (0.37) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275640-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2011-11-10 | — | — | US | disclosed |
| US-20110275641-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2011-11-10 | — | — | US | disclosed |
| US-8003645-B2 | type II diabetes; 6-Ethyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine; suppress the fall in MTT reduction capacity by beta -amyloid protein; inhibit impairment of long-term potentiation of hippocampal nerve cells, pyrimidine or 1,3,5 triazine derivatives | BTG INTERNATIONAL LTD. (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20090286809-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286794-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2009-11-19 | — | — | US | disclosed |
| US-7589105-B2 | For example, N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine, 2-methyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine | BTG INTERNATIONAL LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| EP-1473289-B1 | PREVENTIVES OR REMEDIES FOR ALZHEIMER'S DISEASE OR AMYLOID PROTEIN FIBROSIS INHIBITORS CONTAINING NITROGEN-CONTAINING HETEROARYL COMPOUNDS | BTG INT LTD (GB) | 2009-08-05 | — | — | EP | disclosed |
| US-20080182846-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LIMITED (GB) | 2008-07-31 | — | — | US | disclosed |
| US-20050054732-A1 | Preventives or remidies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds | BTG INTERNATIONAL LTD. (GB) | 2005-03-10 | — | — | US | disclosed |
| EP-1473289-A1 | PREVENTIVES OR REMEDIES FOR ALZHEIMER'S DISEASE OR AMYLOID PROTEIN FIBROSIS INHIBITORS CONTAINING NITROGEN-CONTAINING HETEROARYL COMPOUNDS | Sankyo Company, Limited (JP) | 2004-11-03 | — | — | EP | disclosed |
| EP-0565488-B1 | Fluorine free titanocenes and their application | CIBA GEIGY AG (CH) | 1999-04-21 | — | — | EP | disclosed |
| US-5340701-A | Photoinitiators | CIBA-GEIGY CORPORATION (US) | 1994-08-23 | — | — | US | disclosed |
| EP-0565488-A1 | Fluorine free titanocenes and their application | CIBA-GEIGY AG (CH) | 1993-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054732-A1 | Preventives or remidies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds | NAT1, APP, BACE1 | KDM4E 3469/4885KMT2A 3221/4885ALDH1A1 1310/4885 |
| US-20110275641-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | KDM4E 3771/4885KMT2A 2224/4885ALDH1A1 2328/4885 |
| US-20090286794-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | KDM4E 3771/4885KMT2A 2224/4885ALDH1A1 2328/4885 |
| US-20090286809-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | KDM4E 3771/4885KMT2A 2224/4885ALDH1A1 2328/4885 |
| US-20080182846-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | KDM4E 3771/4885KMT2A 2224/4885ALDH1A1 2328/4885 |
| US-20110275640-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | KDM4E 3771/4885KMT2A 2224/4885ALDH1A1 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.